Liraglutide Versus Lixisenatide: Long-Term Cost-Effectiveness of GLP-1 Receptor Agonist Therapy for the Treatment of Type 2 Diabetes in Spain
about
Liraglutide Versus Lixisenatide: Long-Term Cost-Effectiveness of GLP-1 Receptor Agonist Therapy for the Treatment of Type 2 Diabetes in Spain
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 21 February 2017
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Liraglutide Versus Lixisenatid ...... nt of Type 2 Diabetes in Spain
@en
Liraglutide Versus Lixisenatid ...... t of Type 2 Diabetes in Spain.
@nl
type
label
Liraglutide Versus Lixisenatid ...... nt of Type 2 Diabetes in Spain
@en
Liraglutide Versus Lixisenatid ...... t of Type 2 Diabetes in Spain.
@nl
prefLabel
Liraglutide Versus Lixisenatid ...... nt of Type 2 Diabetes in Spain
@en
Liraglutide Versus Lixisenatid ...... t of Type 2 Diabetes in Spain.
@nl
P2093
P2860
P1433
P1476
Liraglutide Versus Lixisenatid ...... nt of Type 2 Diabetes in Spain
@en
P2093
Antonio Ramírez de Arellano
Gabriela Vega-Hernandez
Nana Kragh
Pedro Mezquita-Raya
William J Valentine
P2860
P2888
P304
P356
10.1007/S13300-017-0239-6
P577
2017-02-21T00:00:00Z